Abbott Makes First Xience Submission To FDA As Guidant Biz Boosts Sales

Abbott kicked off the premarket approval submission process July 19 for the Xience everolimus-eluting coronary stent, taking a step closer to capitalizing on its recent acquisition of Guidant's vascular business